Novartis strengthens neuroscience pipeline with $12bn Avidity acquisition
Deal to advance potential first-in-class RNA therapeutics focused on genetic neuromuscular diseases such as Duchenne muscular dystrophy.
List view / Grid view
Deal to advance potential first-in-class RNA therapeutics focused on genetic neuromuscular diseases such as Duchenne muscular dystrophy.
The new biopharmaceutical production facility represents the CDMO’s largest single investment at its headquarters in Lauphei, Germany.
New findings support use of salbutamol MDI formulation in the next-generation low carbon propellant as a more sustainable option for patients with respiratory disease.
The move will boost its oncology pipeline, adding a potential first-in-class anti-BTN3A monoclonal antibody for acute myeloid leukaemia.
The company will instead focus its attention on advancing candidates for modalities that include biologics and ADCs.
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.
The deal will support the biotech in its plans to advance bispecific antibody petosemtamab in multiple oncology indications.
Winners of this year's awards will be revealed during the opening of CPHI Frankfurt 2025.
The deal with the US biopharma could help address metabolic dysfunction-associated steatohepatitis, one of the most prevalent comorbidities of obesity.
Gains access to potential breakthrough atherosclerotic cardiovascular disease biologic therapy pacibekitug.
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
And Eli Lilly and Company’s new oral GLP-1 obesity therapy orforglipron shines in late-phase clinical trials.
Contracts to use a facility at Fujifilm’s North Carolina site as part of moves to onshore its manufacturing.
The EMA’s decision permits WuXi Biologics to progress with commercial manufacturing of a global client’s innovative biologic.
The new appointee has over twenty years of experience in biopharma and extensive senior expertise in oncology.